AUTHOR=Guo Jianhao , Hao Xing , Wang Rongrong , Lian Ke , Jiang Jun , Chen Na , Feng Zhiying , Rao Yuefeng 

TITLE=MTHFR polymorphism's influence on the clinical features and therapeutic effects in patients with migraine: An observational study

JOURNAL=Frontiers in Neurology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1074857

DOI=10.3389/fneur.2022.1074857

ISSN=1664-2295

ABSTRACT=<sec><title>Objective</title><p>Our study aimed to evaluate the influence of methylenetetrahydrofolate reductase (<italic>MTHFR</italic>) polymorphism on the clinical features and therapeutic effects in patients with migraine.</p></sec><sec><title>Methods</title><p>The data of 135 patients with migraine were collected from January 2021 to December 2021. The <italic>MTHFR</italic> C677T polymorphism was analyzed. The pain intensity was evaluated using a numerical rating scale (NRS) during treatment. The levels of folic acid, homocysteine (Hcy), vitamin B12, interleukin-2 (IL-2), IL-4, and ferritin, and changes of NRS were compared between folic acid and conventional treatment groups stratified by different genotypes of <italic>MTHFR</italic> in migraine patients.</p></sec><sec><title>Results</title><p>The levels of Hcy and ferritin in male patients were higher than that in female patients (<italic>P</italic> &lt; 0.05); Compared with CC and CT genotype groups, the TT genotype group showed significantly higher Hcy levels (<italic>P</italic> &lt; 0.05) and lower folic acid levels (<italic>P</italic> &lt; 0.05); In both folic acid and conventional treatment groups, a significant decrease in NRS score was observed in different genotypes post-treatment (<italic>P</italic> &lt; 0.05). Patients with TT genotype in the folic acid treatment group showed better therapeutic efficacy than conventional treatment group (<italic>P</italic> &lt; 0.05). There is no significant difference in the therapeutic efficacy in other genotypes between the two groups (<italic>P</italic> &gt; 0.05).</p></sec><sec><title>Conclusion</title><p>The <italic>MTHFR</italic> C677T genotyping may provide a new method to guide and optimize individualized medication for migraine patients.</p></sec>